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A B S T R A C T
The relation between progression of cerebral small vessel disease (SVD) and gait decline is uncertain, and dif-
fusion tensor imaging (DTI) studies on gait decline are lacking. We therefore investigated the longitudinal as-
sociations between (micro) structural brain changes and gait decline in SVD using DTI. 275 participants were
included from the Radboud University Nijmegen Diﬀusion tensor and Magnetic resonance imaging Cohort (RUN
DMC), a prospective cohort of participants with cerebral small vessel disease aged 50–85 years. Gait (using
GAITRite) and magnetic resonance imaging measures were assessed during baseline (2006–2007) and follow-up
(2011−2012). Linear regression analysis was used to investigate the association between changes in conven-
tional magnetic resonance and diﬀusion tensor imaging measures and gait decline. Tract-based spatial statistics
analysis was used to investigate region-speciﬁc associations between changes in white matter integrity and gait
decline. 56.2% were male, mean age was 62.9 years (SD8.2), mean follow-up duration was 5.4 years (SD0.2) and
mean gait speed decline was 0.2 m/s (SD0.2). Stride length decline was associated with white matter atrophy
(β= 0.16, p= 0.007), and increase in mean white matter radial diﬀusivity and mean diﬀusivity, and decrease
in mean fractional anisotropy (respectively, β=−0.14, p= 0.009; β=−0.12, p= 0.018; β= 0.10,
p= 0.049), independent of age, sex, height, follow-up duration and baseline stride length. Tract-based spatial
statistics analysis showed signiﬁcant associations between stride length decline and fractional anisotropy de-
crease and mean diﬀusivity increase (primarily explained by radial diﬀusivity increase) in multiple white matter
tracts, with the strongest associations found in the corpus callosum and corona radiata, independent of tradi-
tional small vessel disease markers. White matter atrophy and loss of white matter integrity are associated with
gait decline in older adults with small vessel disease after 5 years of follow-up. These ﬁndings suggest that
progression of SVD might play an important role in gait decline.
1. Introduction
Gait disturbances are prevalent in older adults aged≥65 years and
have important consequences as they can lead to falls, functional de-
pendence and institutionalization (Abellan van Kan et al., 2009; Cesari
et al., 2005). Cerebral small vessel disease (SVD) ranks highest among
vascular causes of gait decline, with evidence mainly coming from
cross-sectional studies (de Laat et al., 2010; Srikanth et al., 2010). A few
studies have investigated whether baseline SVD can predict gait decline
over time. However, their results are inconclusive (Aribisala et al.,
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2013; Rosano et al., 2005; Soumare et al., 2009). In a previous study,
we found no associations between baseline SVD and gait decline after
5 years in our SVD population (Van der Holst et al., 2016 Nov.). One
possible hypothesis is that progression of SVD, rather than baseline SVD
load, is associated with gait decline over time. The results of recent
longitudinal population-based studies investigating the association be-
tween progression of SVD and gait decline are however conﬂicting
(Callisaya et al., 2013; Moscufo et al., 2012; Silbert et al., 2008).
Moreover, these studies did not include the whole SVD spectrum, nor
was the white matter (WM) integrity, which can be assessed using
diﬀusion tensor imaging (DTI), taken into account. Since a recent study
showed that scalar measures of DTI were sensitive markers of SVD
progression (Zeestraten et al., 2016), we hypothesized that changes in
DTI measures are stronger associated with gait decline than progression
of the traditional SVD markers.
Here, we investigated the longitudinal associations between
changes in the traditional SVD markers (WMH, lacunes, microbleeds
and brain atrophy) and changes in WM integrity (assessed by DTI), and
gait decline in a population of adults with SVD, aged 50–85 years, over
a period of 5 years.
2. Methods
2.1. Study population
The Radboud University Nijmegen Diﬀusion tensor and Magnetic
resonance Cohort study (RUN DMC study) prospectively investigates
the risk factors and clinical consequences of brain changes as assessed
by MRI. This cohort study consists of 503 participants with SVD, aged
50–85 years at baseline (2006). The recruitment, study rationale and
protocol of the RUN DMC study have been described elsewhere (van
Norden et al., 2011). Inclusion criteria were age 50–85 years and SVD
on neuroimaging (deﬁned as the presence of WMH or lacunes of pre-
sumed vascular origin) (Erkinjuntti, 2002). All consecutive patients
referred to our outpatient clinic who underwent diagnostic brain ima-
ging for several reasons (e.g. stroke, TIA, cognitive complaints) were
eligible for participation. Main exclusion criteria were: parkinsonism,
dementia, life expectancy< 6 months, non-SVD related WM lesions
and MRI contra-indications (van Norden et al., 2011).
Follow-up assessment was completed in 2012. Of the 503 baseline
participants, 398 participated in the follow-up assessment. For the
present study, 123 participants were additionally excluded, yielding a
ﬁnal sample of 275. Exclusion reasons at baseline and follow-up were:
missing data on MRI and gait data, territorial infarcts, parkinsonism
and conditions associated with gait impairment other than SVD (see
ﬂowchart Fig. 1).
2.2. Standard protocol approvals, registration, and patient consents
All participants signed an informed consent form. The Medical
Review Ethics Committee region Arnhem-Nijmegen approved the
study.
2.3. Gait measurement and gait impairment
The assessment of gait was performed by using a 5.6 m electronic
portable walkway (GAITRite, MAP/CIR Inc., Havertown, PA), which
has an excellent test-retest reliability and validity (Bilney et al., 2003;
Menz et al., 2004). Participants were instructed to walk over the
walkway at their comfortable walking speed. In order to measure
steady-state walking, they started two meters before the walkway and
stopped two meters behind it. The following gait parameters were
averaged over two walks: gait speed (m/s) and its components stride
length (m) (the distance between the heel points of two consecutive
footprints of the same foot) and cadence (number of steps per minute).
Changes in these gait parameters were calculated as the diﬀerence
between follow-up and baseline assessment.
2.4. MRI protocol
A cerebral MRI was acquired on a 1.5-Tesla scanner at baseline and
follow-up (baseline: Magnetom Sonata; follow-up: Magnetom Avanto
Tim (76 × 32); Siemens Medical Solutions, Erlangen, Germany). The
same 8-channel head coil was used at baseline and follow-up. The pro-
tocol included: a T1-weighted 3D magnetization-prepared rapid gra-
dient-echo (MPRAGE) imaging (baseline: repetition time (TR)/echo time
(TE)/inversion time (TI) 2250 ms/3.68 ms/850 ms, ﬂip angle = 15°,
voxelsize 1.0 × 1.0 × 1.0 mm; follow-up: TR/TE/TI 2250 ms/2.95 ms/
850 ms, ﬂip angle = 15°, voxelsize 1.0 × 1.0 × 1.0 mm); a Fluid-atte-
nuated inversion recovery (FLAIR) sequence (baseline: TR/TE/TI
9000 ms/84 ms/2200 ms, voxelsize 1.2 × 1.0 × 5.0 mm (interslice gap
1 mm); follow-up: TR/TE/TI 14240 ms/89 ms/2200 ms, voxelsize
1.2 × 1.0 × 2.5 mm (interslice gap 0.5 mm); a transversal
T2 ∗ weighted gradient echo sequence (baseline and follow-up: TR/TE
800 ms/26 ms, voxelsize 1.3 × 1.0 × 5.0 mm (interslice gap 1 mm))
and a DTI sequence (baseline: TR/TE 10100 ms/93 ms, voxelsize
2.5 × 2.5 × 2.5 mm; 4 unweighted scans, 30 diﬀusion weighted scans
with b-value = 900 s/mm2; follow-up: TR/TE 10200 ms/95 ms, vox-
elsize 2.5 × 2.5 × 2.5 mm; 7 unweighted scans, 61 diﬀusion weighted
scans with b-value = 900 s/mm2).
2.5. Traditional SVD markers and brain volumetry
Traditional SVD makers (WMH, lacunes and microbleeds) were
rated according to the STRIVE criteria (Wardlaw et al., 2013). Lacunes
were manually rated on FLAIR/T1-weighted scans and microbleeds on
T2 ∗ -weighted MRI scans by raters blinded to clinical data. The follow-
up FLAIR images were resliced to match the slice thickness of baseline
FLAIR images, limiting the diﬀerences in partial volume eﬀects between
baseline and follow-up scans. To determine the eﬀects of change in slice
thickness of the FLAIR sequence, we calculated WMH volumes for odd
and even slices separately. Intrarater and interrater reliabilities were
good (for lacunes: weighted kappa values 0.87 and 0.95, respectively,
and for microbleeds: 0.85 and 0.86, respectively). WMH were seg-
mented by using an in-house developed semi-automatic detection
method on baseline and follow-up FLAIR sequences (Ghafoorian et al.,
2016). All scans were visually checked by 1 rater and corrections were
made when segmentation failures had occurred. Total WMH volume
was calculated by summing all segmented areas multiplied by slice
thickness.
Automated segmentation on T1 images of baseline and follow-up
was performed using Statistical Parametric Mapping 12 uniﬁed seg-
mentation routines (SPM12; Wellcome Department of Cognitive
Neurology, University College London, United Kingdom, http://www.
ﬁl.ion.ucl.ac.uk/spm/software/spm12/), in order to obtain gray matter
(GM), WM and cerebrospinal ﬂuid (CSF) probability maps. To avoid the
erroneous segmentation of WM regions with WMH as GM, the T1
images were ﬁrst corrected using the binary maps of WMH by replacing
the voxel intensities of WMH with the average intensity of the normal-
appearing WM on the T1 images. The volumes were calculated by
summing all the voxel volumes belonging to the tissue class. All images
were visually checked for co-registration errors and motion and/or
segmentation artifacts. Total brain volume was taken as the sum of total
GM and WM volume. GM volume was composed of the volume of the
neocortex, basal ganglia and thalamus.
To account for inter-scan-eﬀects, we corrected the normalized
follow-up brain volumes for the diﬀerence in intracranial volume (ICV;
sum of GM, WM and CSF) between baseline and follow-up by multi-
plying all volumes by the factor ‘ICV baseline/ICV follow-up’. Next, all
volumes were normalized to the baseline ICV to adjust for head size
(Colliot et al., 2008). Note that all brain volume represent relative
volume (% of the intracranial volume). We calculated brain volume
H.M. van der Holst et al. NeuroImage: Clinical 17 (2018) 731–738
732
change and changes in the number of lacunes and microbleeds as the
diﬀerence between follow-up and baseline.
2.6. DTI analysis
Diﬀusion data were preprocessed and analyzed according to a pre-
vious described procedure (van Norden et al., 2011) for baseline and
follow-up DTI scans. In short, after eddy current and motion artifacts
corrections on the raw diﬀusion data, we created fractional anisotropy
(FA), mean diﬀusivity (MD), axial diﬀusivity (AD) and radial diﬀusivity
(RD) images using DTIFit within FSL. Next, the DTI images between two
time-points were ﬁrst registered to a half-way space to limit the eﬀects
of partial volume, after which these images were fed into the tract-
based spatial statistics (TBSS) pipeline (Smith et al., 2006). An FA
skeleton was created by thinning the mean FA image based on the FA
values. This skeleton was then thresholded at 0.3 to include major WM
tracts. The images of MD, AD and RD were subsequently projected on
this mean FA skeleton, by applying the projection vectors from each
participant's FA-to-skeleton transformation. Changes in the diﬀusion
parameters were derived by calculating the diﬀerence between DTI
measures of the skeleton at follow-up and baseline.
2.7. Statistical analysis
Statistical analyses were performed using IBM (Armonk, NY) SPSS
Statistics 20. To compare the baseline characteristics of participants
who were included and those not, we used age and sex-adjusted
ANCOVA or logistic regression analysis. For those included, gait and
imaging characteristics at baseline and follow-up were compared by
using a paired t-test, Wilcoxon signed rank test or McNemar test when
appropriate. Multiple linear regression analysis was used to investigate
the association between change in each gait variable and change in the
diﬀerent MRI and DTI measures. Since the baseline imaging markers
were not associated with gait decline (Van der Holst et al., 2016 Nov.),
these measures were not included in the subsequent analyses. Adjust-
ments were made for age, sex, follow-up duration (time between
baseline and follow-up assessment), height and baseline gait variable.
WMH volume was log transformed, because of the skewed distribution.
Fig. 1. Flowchart of the study sample
Abbreviations: DTI: diﬀusion tensor imaging; MRI: magnetic resonance imaging; SVD: small vessel disease.
Of the 503 baseline participants, 2 participants were lost to follow-up, 49 had died and 54 refused an in-person follow-up examination, but their clinical endpoints were available; 398
participated in the follow-up assessment. For the present study, we included 275 participants, 123 participants were additionally excluded because of because of (i) MRI contra-
indications, MRI artifacts or missing values at follow-up (n= 46), (ii) missing data on follow-up GAITRite (n= 12) (because they were wheelchair bound, because of home visit or
because of technical problems), (iii) territorial infarcts at baseline and follow-up imaging (n= 43), because these infarcts were considered as a potential confounder, (iv) conditions
associated with gait impairment other than SVD which prevented participants from walking unaided at baseline and follow-up (n= 13) (joint fusion, severe arthritis, severe poly-
neuropathy, leg amputation, severe vision problems, severe cardiopulmonary diseases, severe peripheral arterial disease and psychogenic gait disturbance), (v) parkinsonism during
follow-up examination (n= 6), because apart from SVD other pathologies as amyloid pathology, Lewy body pathology and nigrastriatal dopaminergic loss could play a role in gait
deterioration in these patients, and (vi) DTI artifacts (n= 3).
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The variance inﬂation factor (VIF) was calculated for all regression
models to test for the presence of multicollinearity. The VIF scores were
low for all models (scores were below 3, where VIF-scores> 5 are
considered to reﬂect high multicollinearity). Regression coeﬃcients
were presented as standardized beta-values.
Voxel-wise statistical analyses for changes in TBSS data and in-
dividual gait variables were performed by using permutation-based
statistical interference tool for non-parametric approach as part of the
FSL toolbox (randomize). The number of permutation tests was set at
5000. Signiﬁcant associations were determined by using a threshold-
free cluster enhancement with a p-value < 0.05, corrected for multiple
comparisons. Adjustments were made for follow-up duration, age, sex,
height and baseline gait variable (model A) and additionally for
changes in MRI measures (including WMH volume, number of lacunes
and microbleeds, WM and GM volume) (model B).
3. Results
The total study population consisted of 275 participants with a
mean (SD) follow-up duration of 5.4 (0.2) years and a mean age at
baseline of 62.9 (8.2) years; 56.4% was male. Characteristics of the
participants included in this study and those not included are shown in
Table 1. Those not included were older, had a poorer cognitive per-
formance, slower gait speed, higher WMH volume, more lacunes, lower
WM and GM volume and lower FA and higher MD values of the WM.
Table 2 shows the gait and imaging characteristics of our study
population at baseline and follow-up. Mean gait speed decline was
0.2 m/s (SD0.2) over 5 years (p < 0.001, one sample t-test), mainly
due to reduction in stride length (mean decline of 0.2 m (SD0.1),
p < 0.001). We found a non-signiﬁcant decrease of cadence (mean
decline 0.9 steps/min (SD7.5), p= 0.06).
There was a signiﬁcant increase of WMH volume, presence of la-
cunes and microbleeds and MD, RD and AD values of WM tracts be-
tween baseline and follow-up. A signiﬁcant decrease was seen for WM
and GM volume and FA value of the WM tracts during follow-up
(Table 2).
3.1. Progression of traditional SVD markers and gait decline
A decline in WM volume was associated with a decline in stride
length (β= 0.16, p= 0.007), after adjustment for age, sex, follow-up
duration, height, and baseline stride length (Table 3). No signiﬁcant
associations were found for changes in stride length and the other SVD
markers, or for changes in gait speed or cadence and changes in all
traditional SVD markers.
3.2. Changes in DTI parameters and gait decline
Only signiﬁcant associations were found for changes in DTI mea-
sures and changes in stride length, and not for changes in gait speed or
cadence. An increase of RD value and MD value of WM tracts was as-
sociated with a decline in stride length (respectively, β=−0.14,
p= 0.009; β=−0.12, p= 0.018), and to a lesser extent between a
decrease of FA and stride length decline (β= 0.10, p= 0.049)
(Table 3).
Our longitudinal TBSS analysis showed signiﬁcant associations be-
tween an increase of MD (primarily explained by an increase of RD) and
to a lesser extent decrease of FA and decline in stride length (Fig. 2 and
Fig. 3), independent of traditional SVD markers. These associations
were primarily found in the whole corpus callosum, and bilateral su-
perior and posterior corona radiata (p < 0.005). We did not ﬁnd any
evidence of laterality and there was also involvement of corticospinal
tracts within the corona radiata. In contrast, no signiﬁcant associations
were found between change in AD and decline in stride length or be-
tween changes in DTI measures and decline in gait speed or cadence
after additionally controlling for the traditional SVD markers (data not
shown).
Table 1
Baseline characteristics of the study population.
Baseline characteristics Participants
included
n = 275
Participants not
included
n = 228
p-value for
diﬀerence
Demographics
Age, mean (SD), years 62.9 (8.2) 69.0 (8.3) < 0.001a
Male sex, No. (%) 155 (56.4) 129 (56.6) 0.96b
MMSE score, mean (SD) 28.5 (1.5) 27.7 (1.8) 0.004a
Gait characteristics n = 275 n=224c
Gait speed, mean (SD),
m/s
1.4 (0.2) 1.2 (0.3) < 0.001a
Gait impairment
(< 1.0 m/s), no. (%)
12 (4.4) 58 (25.9) < 0.001b
Imaging measuresd n = 275 n=227e
WMH volume, median
(IQR), mL
2.2 (0.8–6.3) 7.2 (2.6–15.9) 0.001a
WM volume, mean (SD),
mL
467.6 (37.9) 439.6 (50.2) < 0.001a
GM volume, mean (SD),
mL
622.8 (49.1) 586.8 (50.2) < 0.001a
Lacunes presence, No.
(%)
44 (16.0) 88 (38.6) < 0.001b
Microbleeds presencef,
No. (%)
39 (14.3) 44 (19.5) 0.81b
WM global FA, mean
(SD)
0.33 (0.02) 0.32 (0.02)g 0.01a
WM global MD, mean
(SD), ×10−3 mm2/s
0.88 (0.04) 0.91 (0.05)g < 0.001a
Abbreviations: FA: fractional anisotropy; GM: gray matter; IQR: interquartile range; MD:
mean diﬀusivity; MMSE: Mini Mental State Examination; SD: standard deviation; WM:
white matter; WMH: white matter hyperintensity.
a Age and sex adjusted using ANCOVA.
b Age and sex adjusted using logistic regression.
c 4 participants were excluded because of missing values on baseline gait.
d Brain volumes are represented normalized to the total intracranial volume.
e 1 participant was excluded because of imaging artifacts.
f 2 participants in both groups were excluded because of missing values of baseline
microbleeds.
g 3 participants were excluded because of baseline DTI artifacts.
Table 2
Comparison of gait and imaging measures at baseline and follow-up (n = 275).
Characteristic Baseline Follow-up p-value
Gait characteristics
Gait speed, mean (SD), m/s 1.38 (0.21) 1.19 (0.21) < 0.001a
Stride length, mean (SD), m 1.46 (0.18) 1.26 (0.18) < 0.001a
Cadence, mean (SD), steps/min 113.9 (9.4) 113.0 (9.3) 0.06a
Imaging measures
WMH volume, median (IQR), mL 2.2 (0.8–6.3) 2.8 (1.2–8.0) < 0.001b
WM volume, mean (SD), mL 467.6 (37.9) 457.0 (42.8) < 0.001a
GM volume, mean (SD), mL 622.8 (49.1) 612.0 (50.2) < 0.001a
Lacunes presence, no. (%) 44 (16.0) 61 (22.2) < 0.001c
Microbleeds presenced, no. (%) 39 (14.3) 56 (20.4) < 0.001c
FA of skeleton, mean (SD) 0.49 (0.03) 0.47 (0.03) < 0.001a
MD of skeleton, mean (SD),
×10−3 mm2/s
0.80 (0.04) 0.82 (0.05) < 0.001a
Abbreviations: AD: axial diﬀusivity; FA: fractional anisotropy; GM: gray matter; IQR:
interquartile range; MD: mean diﬀusivity; RD: radial diﬀusivity; SD: standard deviation;
WM: white matter; WMH: white matter hyperintensity.
a Paired t-test.
b Wilcoxon signed rank test.
c McNemar test.
d Respectively 2 and 1 participant(s) had missing values of microbleeds at baseline and
follow-up.
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4. Discussion
In this longitudinal study, we found that WM atrophy and loss of
WM integrity (indicated by an increase of MD and RD, and to a lesser
extent decrease of FA) were associated with gait decline by aﬀecting
stride length in older adults with SVD after 5 years of follow-up.
Changes in DTI measures associated with stride length decline were
primarily found in corpus callosum, and posterior and superior corona
radiata, and were independent of traditional SVD markers. In contrast,
progression of the other SVD markers, including increase of WMH vo-
lume, number of lacunes and microbleeds and GM atrophy, were not
associated with gait decline.
Main strengths of this longitudinal and single-center study include
the quantitative assessment of gait parameters on the same GAITRite at
baseline and follow-up, the follow-up duration of 5.4 years, in which
participants showed a signiﬁcant gait decline and progression of SVD,
and the exclusion of participants with conditions associated with gait
impairment other than SVD which allowed us to further elucidate the
role of SVD in gait decline.
Several methodological issues need to be addressed. First, the
dropout rate (45% of the study population) may have resulted in at-
trition bias. However, as those who were not included had a higher load
of SVD and a slower gait at baseline it may be that the found associa-
tions have been underestimated. Second, due to the observational de-
sign of our study, causal inference cannot be reliably made. The pos-
sibility of reverse causality, indicating that gait deterioration leads to a
Table 3
Association between changes in imaging measures and changes in gait.
Change in gait parameters
Change in imaging measures Δ gait speed
(m/s)
Δ stride length
(m)
Δ cadence
(steps/min)
ΔWMH volumea, mL −0.03 −0.05 0.02
ΔWM volume, mL 0.10 0.16** 0.04
ΔGM volume, mL 0.08 0.10 0.06
ΔLacunes, no. 0.04 0.01 0.06
ΔMicrobleeds, no. −0.09 −0.10 −0.07
ΔFA of skeleton 0.06 0.10* 0.01
ΔMD of skeleton,
×10−4 mm2/s
−0.06 −0.12* 0.05
ΔRD of skeleton,
×10−4 mm2/s
−0.07 −0.14** 0.02
ΔAD of skeleton,
×10−4 mm2/s
0.01 −0.03 0.07
Abbreviations: AD: axial diﬀusivity; FA: fractional anisotropy; GM: gray matter; MD:
mean diﬀusivity; RD: radial diﬀusivity; WM: white matter; WMH: white matter hyper-
intensity.
Data are standardized beta-values.
Adjustments were made for age, sex, follow-up duration, height and baseline gait para-
meter (baseline gait speed, stride length or cadence respectively).
*p < 0.05, **p < 0.01.
Bold values indicate signiﬁcance at p < 0.05, false discovery rate-corrected.
Δ indicates diﬀerence between follow-up and baseline assessment.
a Log transformed.
Fig. 2. Association between decrease in stride length and changes in diﬀusion tensor imaging measures after 5 years of follow-up.
Voxel-wise analysis of the association between changes in stride length (in centimeters) and changes in diﬀerent diﬀusion tensor imaging measures, thresholded at P < 0.05 and
corrected for multiple comparisons. Adjustments were made for age, sex, follow-up duration, height and baseline stride length (model 1) and additionally for changes in cerebral small
vessel disease characteristics (white matter hyperintensities, number of lacunes, microbleeds and gray matter and white matter volume) (model 2). These images are superimposed onto
the spatially normalized Montreal Neurological Institute (MNI) stereotactic space fractional anisotropy map. The x, y, and z coordinates represent the MNI coordinates of each slide.
H.M. van der Holst et al. NeuroImage: Clinical 17 (2018) 731–738
735
sedentary lifestyle and thereby to progression of SVD and reduction of
microstructural integrity, cannot be excluded. Third, despite our careful
clinical investigation to exclude participants with other factors related
to decline in gait from this substudy, including polyneuropathy, vision
problems, rheumatic disease, degenerative joint disease, cardio-
pulmonary diseases and peripheral arterial disease, we cannot rule out
the possibility of residual confounding by unmeasured variables that
are related to both change in the microstructural integrity of the white
matter and gait decline. Fourth, the eﬀect of scanner upgrade (baseline:
Sonata and follow-up: Avanto MRI scanner, using the same Siemens
head coil) is unknown. It has previously been found that the volumetric
measures remained reliable, even after scanner upgrade and that the
variance of the volume diﬀerences relative to test-retest reproducibility
did not signiﬁcantly change, however it may introduce a bias in the
mean volume diﬀerences (Jovicich et al., 2009). Therefore, our results
on macrostructural brain changes have to be interpreted with caution.
Also, the change in slice thickness of the FLAIR images at follow-up
could have an impact on the segmentation results of the WMH. Caution
has been taken to limit the eﬀect of the change in slice thickness by
reslicing to match slice thickness of baseline FLAIR images. Ad-
ditionally, we calculated WMH volumes for odd and even slices sepa-
rately and found no signiﬁcant diﬀerences in the eﬀects of change in
slice thickness of the FLAIR images. The DTI protocol did not diﬀer
between baseline and follow-up, except from the number of diﬀusion
weighted scans (30 versus 61 diﬀusion-encoding gradient directions).
The eﬀect of number of gradient directions is however limited, as we
have applied the diﬀusion tensor model (with 6 degree of freedom).
With regard to the scanner upgrade, a previous study showed that the
DTI parameters did not diﬀer between the scanners (Huang et al.,
2012). Therefore, we consider the DTI results as robust.
We found that a decline in gait speed is primarily caused by a de-
cline in stride length and not in cadence in our population. This is in
line with our previous ﬁnding that stride length is a more sensitive
marker for gait abnormalities in SVD compared to cadence and gait
speed (de Laat et al., 2010).
Furthermore, we showed that WM atrophy and changes in DTI
measures were associated with gait decline in older adults with SVD.
The association between WM atrophy and gait decline has been re-
ported earlier by (Callisaya et al. (2013). In contrast to this study, we
found no signiﬁcant associations between gait decline and progression
of WMH volume, or progression of other traditional SVD markers.
These ﬁndings suggest that diﬀusional measures have the potential to
serve as a better disease marker of SVD burden than the standard MRI
measures, which could be used in future studies. There are several
reasons for the limitations of the traditional markers based on
conventional MRI, which need to be taken into account when planning
future studies (De Guio et al., 2016). First, quantiﬁcation of lesions,
such as white matter hyperintensities and lacunes, can be labor-in-
tensive and subjected to bias due to segmentation error. Second, the
volume of these lesions rely on dichotomization of the tissue (into
normal and abnormal), disregarding the continuous degree of severity.
In contrast, DTI can capture the gradual changes both within the lesions
and in the normal-appearing white matter. Third, the associations be-
tween these lesions and clinical symptoms are generally weak or in-
consistent (Holtmannspotter et al., 2005; Nitkunan et al., 2008).
Fourth, the diﬀusional measures correlate more stronger with clinical
symptoms, including gait (de Laat et al., 2011), cross-sectionally and
longitudinally (this study). Several longitudinal studies have shown
that diﬀusional measures had the smallest sample size estimates com-
pared to other SVD markers (Baykara et al., 2016; Benjamin et al.,
2016). Fourth, the limited contribution of each of these SVD markers to
gait decline might also be explained by the possible regional-speciﬁc
associations of these SVD markers on gait decline or a threshold-eﬀect
rather than a dose-dependent relation, as some evidence has been found
for WMH (Soumare et al., 2009). Also, the changes of the traditional
MRI markers of SVD are greater and are easier to detect in more severe
patients (van Leijsen et al., 2017). Since we included a rather healthy
study population covering the whole spectrum of SVD and excluded
severe patients with among other parkinsonism, the variation of MRI
markers over time might less resulting in no signiﬁcant associations
with gait decline. Furthermore, it might be that WM microstructural
integrity is a moderator in the association between progression of tra-
ditional SVD markers and gait decline, as one cross-sectional study
showed that in participants with a greater WMmicrostructural integrity
WMH were less strongly associated with gait in comparison to those
with a low WM microstructural integrity (Rosario et al., 2016).
Regional analysis of DTI determined several WM tracts involved in
gait decline commonly aﬀected by SVD pathology (Srikanth et al.,
2010). Consistent with, and extending our previous cross-sectional
study (de Laat et al., 2011), we demonstrated that the strongest asso-
ciations between changes of DTI measures and decline in stride length
were found in corpus callosum and corona radiata. The corpus callosum
is an important WM tract in motor control, as this region contains
commissural ﬁbers connecting multiple cortical areas involved in gait
planning, initiation and execution, including frontal, parietal and oc-
cipital cortices (Chao et al., 2009). Fibers from these regions converse
into the corona radiata that as such contains projection ﬁbers that are
involved in motor pathways and thus plays a pivotal role in motor
function (Jang, 2009). Also, the involvement of corticospinal tracts
within the corona radiata, which is a critical pathway involved in gait
Mean diffusivity Radial diffusivity
Fig. 3. The scatterplots shows the relation (linear regression) between changes in mean diﬀusivity and radial diﬀusivity values of the signiﬁcant white matter tracts found in tract-based
spatial statistic (TBSS) analysis and changes in stride length (in centimeters), respectively.
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function, could contribute to the decline in stride length observed in
this study. Our results suggest that progression of disruption of these
WM tracts is associated with gait decline in SVD.
We found the strongest association with increase in MD, and espe-
cially RD values of the WM tracts and gait decline. This is consistent
with data from a recent study showing that MD is a more sensitive
marker for SVD progression in comparison to FA in a SVD population
over a period of 3 years (Zeestraten et al., 2016). An increase of MD,
primarily explained by an increase in RD, is thought to represent de-
myelination in homogeneous parallel WM regions (Song et al., 2003),
which might be related to volume reduction of WM. This result might
provide some support for the role of (ischaemic) demyelination in SVD
related gait decline above axonal damage/degeneration (reﬂected by an
increase in AD), which has also been described in neuropathological
studies of SVD (Englund, 2002). However, as DTI measures are de-
pendent on eigenvalue sorting, it may be diﬃcult to obtain reliable
measures in complex WM architecture (e.g. areas with crossing ﬁbers)
or pathology (e.g. SVD) (Wheeler-Kingshott and Cercignani, 2009) and
therefore our results should be interpreted with caution. Our results
might suggest that changes in MD of the WM, especially of the corpus
callosum and corona radiata, could serve as an early marker of gait
decline in an SVD population.
SVD is a dynamic and highly variable disease process with pro-
gression and in some regression of SVD (van Leijsen et al., 2017;
Wardlaw et al., 2017). In a recent study reduction in blood pressure was
associated with reduction in WMH volume and MD over 1 year period
after minor stroke (Wardlaw et al., 2017). This suggests that better
blood pressure control could attenuate or even reverse the WMH
growth and MD increase of the white matter, and consequently could
lead to better gait function over time. The results of randomized con-
trolled trials of blood pressure are however so far mixed. Nevertheless
better vascular risk factors management (including hypertension) re-
mains important in reducing the potential risk of brain pathology and
gait decline.
In conclusion, our data suggest that WM atrophy and loss of WM
integrity, especially of the corpus callosum and corona radiata, are
associated with gait decline over a period of 5 years in older adults with
SVD. These ﬁndings favor a role for WM pathology progression in gait
decline in patients with SVD and should therefore be considered as one
of the possible causes of gait decline. Future studies should investigate
the reproducibility of our results and the potential of DTI as surrogate
and early marker of gait impairment in SVD, for example in clinical
trials. Meanwhile, clinical practitioners should focus on prevention
strategies directed against progression of WM pathology in order to
maintain ambulatory function in an aging society.
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